시장보고서

상품코드

1605724

안데르센-타윌 증후군 치료제 시장 : 치료 유형별, 약물 유형별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Andersen Tawil Syndrome Treatment Market, By Treatment Type, By Drug Class, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 392 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

안데르센-타윌 증후군 치료제 시장 규모는 2023년 17억6,523만 달러로 평가되었고, 2024년부터 2032년까지 연평균 7.2%로 확대될 것으로 예상됩니다.

안데르센-타윌 증후군 치료제 시장 - 시장 역학

유전자 치료의 발전과 원격 의료의 확대로 안데르센-타윌 증후군 치료 시장 성장 촉진

유전자 치료의 발전과 원격 의료 서비스의 확대로 안데르센-타윌 증후군 치료 시장이 크게 성장하고 있습니다. 미국 원격의료 현대화법(U.S. Telehealth Modernization Act)과 같은 이니셔티브가 뒷받침하는 원격의료 플랫폼의 도입으로 원격지 환자들의 전문 의료 서비스 접근성이 증가하고 있습니다. 미국 국립보건원(NIH)과 같은 기관은 안데르센-타윌 증후군을 포함한 유전성 질환에 초점을 맞춘 50개 이상의 활발한 연구를 수행하며 표적 치료법 개발을 위한 연구 자금을 지원하고 있습니다. 또한, 원격 의료가 의료 시스템에 통합되면서 희귀질환 환자의 60%가 이동 없이도 전문의와 상담할 수 있게 되어 관리 체계와 치료 프로토콜을 준수할 수 있게 되어 관리 체계와 치료 프로토콜 준수율이 향상되고 있습니다.

안데르센-타윌 증후군 치료제 시장 - 주요 인사이트

당사의 리서치 애널리스트들의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 매년 약 7.2%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

치료 유형별로는 약수처리가 2023년에 가장 높은 시장 점유율을 보였습니다.

약물 유형별로는 2023년 탄산탈수효소 억제제가 주요 유형으로 부상할 것으로 예상됩니다.

투여 경로별로는 경구 투여가 2023년 주요 유형이었습니다.

지역별로는 북미가 2023년 매출 1위

안데르센-타윌 증후군 치료제 시장 - 세분화 분석 :

안데르센-타윌 증후군 치료제 세계 시장은 치료 유형, 약물 유형, 투여 경로, 최종 사용자, 지역에 따라 세분화됩니다.

시장은 치료 유형에 따라 약수처리와 물리치료의 두 가지 범주로 나뉩니다. 약수처리는 심장 부정맥 및 주기적 마비와 같은 증상을 직접적으로 다루기 때문에 안데르센-타윌 증후군 치료 시장에서 가장 높은 우선순위를 차지합니다. 물리치료는 그 뒤를 이어 장기적인 관리와 환자의 삶의 질을 위해 근력과 운동 능력을 향상시키는 데 중요한 역할을 합니다.

시장은 약물 유형에 따라 탄산탈수효소 억제제, 베타차단제, 칼륨 보충제 등 세 가지로 분류됩니다. 탄산탈수효소 억제제는 주기성 마비 증상의 관리에 효과적이기 때문에 우선적으로 사용되며, 베타 차단제는 안데르센-타빌 증후군에서 흔히 나타나는 부정맥을 치료하는 데 사용됩니다. 칼륨 보충제는 저칼륨 혈증을 개선하고 환자의 근육과 심장 기능을 안정시키는 데 필수적입니다.

안데르센-타윌 증후군 치료제 시장 - 지리적 인사이트

북미가 안데르센-타윌 증후군 치료제 시장을 독점하고 있으며, 그 배경에는 탄탄한 의료 인프라와 희귀질환 연구에 대한 자금 지원 증가가 있습니다. 이 지역은 미국 국립보건원(NIH)이 지원하는 희귀질환 임상연구 네트워크(RDCRN)와 같은 이니셔티브의 혜택을 누리고 있으며, 70개 이상의 유전질환 관련 공동연구를 촉진하고 있습니다. 미국에서는 2023년 안데르센-타윌 증후군에 수반되는 주기성 마비를 치료하기 위한 새로운 칼륨 채널 조절제를 개발하기 위해 주요 제약회사와 생명공학 기업이 중요한 제휴를 맺을 예정입니다. 유럽에서는 유럽의약품청(EMA)이 여러 임상시험용 의약품을 희귀질환 치료제(희귀의약품)로 지정했습니다. 아시아태평양에서는 희귀의약품법(Orphan Drug Act)에 따라 희귀질환 치료제 개발을 장려하는 일본과 같은 국가들의 헬스케어에 대한 인식이 높아지고 정부의 지원이 시장 전망을 뒷받침하고 있습니다. 또한, 호주의 유명 의료 서비스 제공업체들이 원격 의료 플랫폼을 출시하여 특히 지방의 환자들이 더 나은 질병 관리를 위해 전문 의료진에 대한 접근성을 향상시키고 있습니다.

안데르센-타윌 증후군 치료제 시장 - 경쟁 구도:

안데르센-타윌 증후군 치료제 시장은 대규모 R&D 투자와 대형 제약사의 존재로 북미가 주요 지역으로 부상하고 있으며, 2023년 미국 기반 생명공학 기업이 안데르센-타윌 증후군과 관련된 주기성 마비의 유망한 치료제인 칼륨 채널 조절제 개발을 가속화하기 위해 유럽 기업과의 전략적 합병을 발표했습니다. 칼륨 채널 조절제 개발을 가속화하기 위해 유럽 기업과의 전략적 합병을 발표했습니다. 또한, 학계 및 산업계 리더들과의 공동 연구를 통해 새로운 유전자 치료에 초점을 맞춘 40개 이상의 임상시험이 진행되고 있습니다. 유럽도 중요한 역할을 하고 있으며, 여러 제약사가 EMA로부터 희귀질환 치료제 지정을 받아 이 지역의 경쟁력을 높이고 있습니다. 한편, 아시아태평양에서는 최근 일본 기업들이 희귀 유전성 질환을 대상으로 한 획기적인 유전자 치료 플랫폼을 출시하며 시장에서의 입지를 강화하고 있습니다. 원격 의료 플랫폼의 세계 확산과 함께 이러한 이니셔티브는 안데르센-타윌 증후군 치료 시장의 역동적이고 경쟁적인 성격을 뒷받침합니다.

서론
북미
- 개요
- 북미 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 안데르센-타윌 증후군 치료 업계

경쟁 대시보드
기업 개요
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Johnson &Johnson Services, Inc.
- Merck &Co., Inc.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Others

제13장 애널리스트의 전방위 전망

LSH 24.12.18

REPORT HIGHLIGHT

Andersen Tawil Syndrome Treatment Market size was valued at USD 1,765.23 Million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

The Andersen-Tawil Syndrome Treatment Market focuses on therapeutic solutions for a rare genetic disorder characterized by periodic paralysis, cardiac arrhythmias, and distinctive physical features. Growing advancements in genetic research and precision medicine have fueled the development of targeted therapies, enhancing patient outcomes. Increasing awareness among healthcare professionals and improved diagnostic capabilities have contributed to the early detection of the syndrome, with nearly 70% of cases now identified through genetic testing. However, the high cost of treatment and limited availability of specialized healthcare facilities pose significant challenges. Market opportunities include the development of novel therapies and the expansion of telemedicine services to support remote patient management.

Andersen Tawil Syndrome Treatment Market- Market Dynamics

Advancements in Genetic Therapies and Telemedicine Expansion Propel Growth in the Andersen-Tawil Syndrome Treatment Market

Advancements in genetic therapies, coupled with the expansion of telemedicine services, are significantly boosting the Andersen-Tawil Syndrome Treatment Market. The implementation of telehealth platforms, supported by initiatives such as the U.S. Telehealth Modernization Act, has increased access to specialized care for patients in remote areas. Institutions like the National Institutes of Health (NIH) are funding research to develop targeted therapies, with over 50 active studies focusing on genetic disorders, including Andersen-Tawil Syndrome. Moreover, the growing integration of telemedicine into healthcare systems has allowed nearly 60% of rare disease patients to consult specialists without the need for travel, improving management and adherence to treatment protocols.

Andersen Tawil Syndrome Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Medication was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Carbonic anhydrase inhibitors were the leading type in 2023

Based on Route of Administration segmentation, Oral administration was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Andersen Tawil Syndrome Treatment Market- Segmentation Analysis:

The Global Andersen Tawil Syndrome Treatment Market is segmented based on Treatment Type, Drug Class, Route of Administration, End-User, and Region.

The market is divided into two categories based on Treatment Type: Medication and Physical Therapy. Medication holds the highest priority in the Andersen-Tawil Syndrome Treatment Market, as it directly addresses symptoms like cardiac arrhythmias and periodic paralysis. Physical therapy follows, playing a vital role in improving muscle strength and mobility for long-term management and patient quality of life.

The market is divided into three categories based on Drug Class: Carbonic Anhydrase Inhibitors, Beta-Blockers, and Potassium Supplements. Carbonic anhydrase inhibitors are prioritized for their effectiveness in managing periodic paralysis episodes. Beta-blockers follow, addressing cardiac arrhythmias commonly seen in Andersen-Tawil Syndrome. Potassium supplements hold third priority, essential for correcting hypokalemia and stabilizing muscle and cardiac function in patients.

Andersen Tawil Syndrome Treatment Market- Geographical Insights

North America dominates the Andersen-Tawil Syndrome Treatment Market, driven by robust healthcare infrastructure and increased funding for rare disease research. The region benefits from initiatives like the Rare Disease Clinical Research Network (RDCRN), supported by the National Institutes of Health (NIH), which has facilitated over 70 collaborative studies on genetic disorders. The U.S. also witnessed a key partnership in 2023 between a leading pharmaceutical company and a biotech firm to develop novel potassium channel modulators aimed at addressing periodic paralysis associated with Andersen-Tawil Syndrome. Europe follows closely, with the European Medicines Agency (EMA) granting orphan drug designation to several investigational therapies. In Asia-Pacific, rising healthcare awareness and government support in countries like Japan, where the Orphan Drug Act encourages rare disease treatment development, are boosting market prospects. Furthermore, the launch of a telemedicine platform by a prominent healthcare provider in Australia has increased patient access to specialists, especially in rural regions, supporting better disease management.

Andersen Tawil Syndrome Treatment Market- Competitive Landscape:

The Andersen-Tawil Syndrome Treatment Market is marked by strong competition, with North America emerging as the leading region due to significant R&D investments and the presence of major pharmaceutical players. In 2023, a U.S.-based biotech company announced a strategic merger with a European firm to accelerate the development of potassium channel modulators, a promising treatment for periodic paralysis linked to Andersen-Tawil Syndrome. Additionally, collaborations between academic institutions and industry leaders have resulted in over 40 clinical trials focused on novel genetic therapies. Europe also plays a crucial role, with several pharmaceutical companies receiving orphan drug designations from the EMA, boosting the region's competitive edge. Meanwhile, in the Asia-Pacific, a Japanese firm recently launched a groundbreaking gene therapy platform targeting rare genetic disorders, enhancing its market position. These initiatives, coupled with the increasing adoption of telemedicine platforms globally, underscore the dynamic and competitive nature of the Andersen-Tawil Syndrome Treatment Market.

Recent Developments:

In April 2021, Karo Pharma Aktiebolag acquired Teva Pharmaceuticals to expand its European OTC portfolio and rare disease research. Sun Pharmaceutical Industries Ltd. acquired a 66% stake in Trikaal Mediinfotech and AWACS through its subsidiary, ABCD Technologies LLP.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Others

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Medication
Physical Therapy

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Carbonic Anhydrase Inhibitors
Beta-Blockers
Potassium Supplements

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Specialty Clinics
Research Institutes

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Andersen Tawil Syndrome Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Andersen Tawil Syndrome Treatment Market Snippet by Treatment Type
- 2.1.2. Andersen Tawil Syndrome Treatment Market Snippet by Drug Class
- 2.1.3. Andersen Tawil Syndrome Treatment Market Snippet by Route of Administration
- 2.1.4. Andersen Tawil Syndrome Treatment Market Snippet by End-User
- 2.1.5. Andersen Tawil Syndrome Treatment Market Snippet by Country
- 2.1.6. Andersen Tawil Syndrome Treatment Market Snippet by Region
2.2. Competitive Insights

3. Andersen Tawil Syndrome Treatment Key Market Trends

3.1. Andersen Tawil Syndrome Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Andersen Tawil Syndrome Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Andersen Tawil Syndrome Treatment Market Opportunities
3.4. Andersen Tawil Syndrome Treatment Market Future Trends

4. Andersen Tawil Syndrome Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Andersen Tawil Syndrome Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Andersen Tawil Syndrome Treatment Market Landscape

6.1. Andersen Tawil Syndrome Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Andersen Tawil Syndrome Treatment Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
- 7.1.2. Medication
- 7.1.3. Physical Therapy

8. Andersen Tawil Syndrome Treatment Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 8.1.2. Carbonic Anhydrase Inhibitors
- 8.1.3. Beta-Blockers
- 8.1.4. Potassium Supplements

9. Andersen Tawil Syndrome Treatment Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Intravenous

10. Andersen Tawil Syndrome Treatment Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Specialty Clinics
- 10.1.4. Research Institutes

11. Andersen Tawil Syndrome Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Andersen Tawil Syndrome Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Andersen Tawil Syndrome Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. Amgen Inc.
- 12.2.3. AstraZeneca PLC
- 12.2.4. Bayer AG
- 12.2.5. Bristol-Myers Squibb Company
- 12.2.6. Eisai Co., Ltd.
- 12.2.7. F. Hoffmann-La Roche AG
- 12.2.8. GlaxoSmithKline plc
- 12.2.9. Johnson & Johnson Services, Inc.
- 12.2.10. Merck & Co., Inc.
- 12.2.11. Mylan N.V.
- 12.2.12. Novartis AG
- 12.2.13. Pfizer Inc.
- 12.2.14. Sanofi S.A.
- 12.2.15. Takeda Pharmaceutical Company Limited
- 12.2.16. Teva Pharmaceutical Industries Ltd.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us